<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395666</url>
  </required_header>
  <id_info>
    <org_study_id>NMTRC003B</org_study_id>
    <nct_id>NCT02395666</nct_id>
  </id_info>
  <brief_title>Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission</brief_title>
  <official_title>A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giselle Sholler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beat NB Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Because of Ezra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KC Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spectrum Health Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate a new investigational drug to prevent
      reoccurrence of neuroblastoma that is in remission. This study drug is called DFMO. The
      objectives of this study will be to monitor for safety and look at efficacy of DFMO.

      The safety of the proposed dosing regimen in this trial will be tested by an on-going
      risk/benefit assessment during the study. A patient benefiting from treatment, not
      progressing on therapy, and in the absence of any safety issues associated with DFMO may
      continue on treatment up to 27 cycles with the expectation that there will be an overall
      clinical benefit.

      The procedures involved in this study include Medical history, Physical exam, Vital signs
      (blood pressure, pulse, temperature), Blood tests, Urine tests, MRI or CT scan of the
      tumor(s), meta-iodobenzylguanidine (MIBG) scans, and Bone marrow aspirations. All of these
      tests and procedures are considered standard of care for this population. Drug administration
      is also part of this protocol, including an investigational new drug called DFMO.

      The proposed dosing regimen is an oral dose of DFMO tablets two times a day for each day
      while on study. There will be 27 cycles. Each cycle will be 28 days in length.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Actual">March 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Event Free Survival (EFS) During Study.</measure>
    <time_frame>2 Years</time_frame>
    <description>To evaluate the preventative activity of DFMO as a single agent in patients that are in remission based on: Event free survival (EFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Survival (OS)</measure>
    <time_frame>2 Years</time_frame>
    <description>To evaluate the preventative activity of DFMO as a single agent in patients with neuroblastoma who are in remission based on: Overall Survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2 years</time_frame>
    <description>To continue to determine the safety and tolerability of DFMO as a single agent and in pediatric and young adult patients with high risk neuroblastoma that is in remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test the Association of Survival With ODC1 Genotype</measure>
    <time_frame>2 years</time_frame>
    <description>Tests (p-value) of the association of survival with ODC1 single nucleotide polymorphism rs2302616 genotype.
Blood: microRNA analysis as predictor of DFMO effect, ornithine decarboxylase (ODC) single nucleotide polymorphism (SNP) analysis in DNA isolated from nucleated cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Tumor Cell Analysis</measure>
    <time_frame>5 years</time_frame>
    <description>circulating tumor cell analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days</time_frame>
    <description>Pharmacokinetic assay Cmax/D
Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC)</measure>
    <time_frame>0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose on two different days</time_frame>
    <description>Pharmacokinetic assay AUC(0-6 hr)/D
Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Peak Plasma Concentration (Tmax)</measure>
    <time_frame>0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose on two different days</time_frame>
    <description>Pharmacokinetic assay- tmax, hr
Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>DFMO twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFMO</intervention_name>
    <description>Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.</description>
    <arm_group_label>DFMO twice daily</arm_group_label>
    <other_name>eflornithine HCl</other_name>
    <other_name>Difluoromethylornithine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 0-21 years at the time of diagnosis.

          -  Diagnosis: histologic verification at either the time of original diagnosis or a
             previous relapse of high risk neuroblastoma.

          -  Disease Status: Neuroblastoma that is in remission

          -  First dose of study medication must be greater than 30 days from completion of
             cytotoxic and antibody therapy and less than 120 days from previous therapy

          -  A negative serum or urine pregnancy test is required for female subjects of child
             bearing potential (onset of menses or ≥13 years of age).

          -  Both male and female post-pubertal study subjects need to agree to use one of the more
             effective birth control methods during treatment and for six months after treatment is
             stopped. These methods include total abstinence (no sex), oral contraceptives (&quot;the
             pill&quot;), an intrauterine device (IUD), levonorgestrel implants (Norplant), or
             medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be
             used, contraceptive foam with a condom is recommended.

          -  Absolute Neutrophil Count (ANC) &gt; 500/μl and platelet count &gt;50,000/μl

          -  Organ Function Requirements: Subjects must have adequate liver function as defined by:

               -  Aspartate Aminotransferase (AST) and Alanine transaminase (ALT) &lt;10x upper limit
                  of normal

               -  Serum bilirubin must be ≤ 2.0 mg/dl

               -  Serum creatinine based on age/gender

          -  Informed Consent: All subjects and/or legal guardians must sign informed written
             consent. Assent, when appropriate, will be obtained according to institutional
             guidelines

        Exclusion Criteria:

          -  Lansky score &lt; 60%

          -  Body Surface Area (BSA) (m2) of &lt;0.25

          -  Investigational Drugs: Subjects who are currently receiving another investigational
             drug are excluded from participation.

          -  Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are
             not eligible. Subjects must have fully recovered from the effects of prior
             chemotherapy (hematological and bone marrow suppression effects).

          -  Infection: Subjects who have an uncontrolled infection are not eligible until the
             infection is judged to be well controlled in the opinion of the investigator.

          -  Subjects who, in the opinion of the investigator, may not be able to comply with the
             safety monitoring requirements of the study, or in whom compliance is likely to be
             suboptimal, should be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giselle Saulnier-Sholler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Spectrum Health Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital Johns Hopkins Medicine</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Clinics on Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center and Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Carrell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dell Children's Blood and Cancer Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer and Hematology Centers</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.beatcc.org</url>
    <description>Beat Childhood Cancer Consortium website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2015</study_first_posted>
  <results_first_submitted>February 14, 2020</results_first_submitted>
  <results_first_submitted_qc>April 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 3, 2020</results_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Spectrum Health Hospitals</investigator_affiliation>
    <investigator_full_name>Giselle Sholler</investigator_full_name>
    <investigator_title>Beat Childhood Cancer Chair</investigator_title>
  </responsible_party>
  <keyword>Neuroblastoma in remission</keyword>
  <keyword>Relapsed Neuroblastoma</keyword>
  <keyword>Refractory Neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eflornithine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT02395666/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stratum 1</title>
          <description>Subjects that are in remission at the end of upfront therapy defined as chemotherapy (5-7 cycles), surgery as indicated, consolidation therapy as indicated, radiation therapy as indicated, anti-GD2 antibody therapy with retinoic acid up to 6 cycles.
Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.</description>
        </group>
        <group group_id="P2">
          <title>Stratum 2</title>
          <description>Subjects that are in remission after any previous relapse or refractory therapy.
Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stratum 1</title>
          <description>Subjects that are in remission at the end of upfront therapy defined as chemotherapy (5-7 cycles), surgery as indicated, consolidation therapy as indicated, radiation therapy as indicated, anti-GD2 antibody therapy with retinoic acid up to 6 cycles.
Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.</description>
        </group>
        <group group_id="B2">
          <title>Stratum 2</title>
          <description>Subjects that are in remission after any previous relapse or refractory therapy.
Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" lower_limit="1" upper_limit="17"/>
                    <measurement group_id="B2" value="6.8" lower_limit="1" upper_limit="14"/>
                    <measurement group_id="B3" value="5.1" lower_limit="1" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Event Free Survival (EFS) During Study.</title>
        <description>To evaluate the preventative activity of DFMO as a single agent in patients that are in remission based on: Event free survival (EFS)</description>
        <time_frame>2 Years</time_frame>
        <population>One subject removed from Stratum 1 due to not fitting study criteria upon review</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1</title>
            <description>Subjects that are in remission at the end of upfront therapy defined as chemotherapy (5-7 cycles), surgery as indicated, consolidation therapy as indicated, radiation therapy as indicated, anti-GD2 antibody therapy with retinoic acid up to 6 cycles.
Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2</title>
            <description>Subjects that are in remission after any previous relapse or refractory therapy.
Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event Free Survival (EFS) During Study.</title>
          <description>To evaluate the preventative activity of DFMO as a single agent in patients that are in remission based on: Event free survival (EFS)</description>
          <population>One subject removed from Stratum 1 due to not fitting study criteria upon review</population>
          <units>percentage of subjects without an event</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="80" upper_limit="88"/>
                    <measurement group_id="O2" value="51" lower_limit="43" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Survival (OS)</title>
        <description>To evaluate the preventative activity of DFMO as a single agent in patients with neuroblastoma who are in remission based on: Overall Survival (OS)</description>
        <time_frame>2 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1</title>
            <description>Subjects that are in remission at the end of upfront therapy defined as chemotherapy (5-7 cycles), surgery as indicated, consolidation therapy as indicated, radiation therapy as indicated, anti-GD2 antibody therapy with retinoic acid up to 6 cycles.
Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2</title>
            <description>Subjects that are in remission after any previous relapse or refractory therapy.
Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Survival (OS)</title>
          <description>To evaluate the preventative activity of DFMO as a single agent in patients with neuroblastoma who are in remission based on: Overall Survival (OS)</description>
          <units>percentage of subjects without an event</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="84" lower_limit="78" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>To continue to determine the safety and tolerability of DFMO as a single agent and in pediatric and young adult patients with high risk neuroblastoma that is in remission.</description>
        <time_frame>2 years</time_frame>
        <population>Stratum 1 and 2 were analyzed together as one safety group as per statistical analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>DFMO Twice Daily</title>
            <description>Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
DFMO: Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>To continue to determine the safety and tolerability of DFMO as a single agent and in pediatric and young adult patients with high risk neuroblastoma that is in remission.</description>
          <population>Stratum 1 and 2 were analyzed together as one safety group as per statistical analysis plan.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Test the Association of Survival With ODC1 Genotype</title>
        <description>Tests (p-value) of the association of survival with ODC1 single nucleotide polymorphism rs2302616 genotype.
Blood: microRNA analysis as predictor of DFMO effect, ornithine decarboxylase (ODC) single nucleotide polymorphism (SNP) analysis in DNA isolated from nucleated cells</description>
        <time_frame>2 years</time_frame>
        <population>Stratum 1 and 2 were analyzed together as one group as per statistical analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>GG, GT, TT</title>
            <description>Tests of the association of survival with ODC1 single nucleotide polymorphism rs2302616 genotype.</description>
          </group>
          <group group_id="O2">
            <title>GG or GT, TT</title>
            <description>Tests of the association of survival with ODC1 single nucleotide polymorphism rs2302616 genotype.</description>
          </group>
          <group group_id="O3">
            <title>GG, GT or TT</title>
            <description>Tests of the association of survival with ODC1 single nucleotide polymorphism rs2302616 genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Test the Association of Survival With ODC1 Genotype</title>
          <description>Tests (p-value) of the association of survival with ODC1 single nucleotide polymorphism rs2302616 genotype.
Blood: microRNA analysis as predictor of DFMO effect, ornithine decarboxylase (ODC) single nucleotide polymorphism (SNP) analysis in DNA isolated from nucleated cells</description>
          <population>Stratum 1 and 2 were analyzed together as one group as per statistical analysis plan.</population>
          <units>p-value</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96"/>
                    <measurement group_id="O2" value="0.58"/>
                    <measurement group_id="O3" value="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Tumor Cell Analysis</title>
        <description>circulating tumor cell analysis</description>
        <time_frame>5 years</time_frame>
        <posting_date>09/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration (Cmax)</title>
        <description>Pharmacokinetic assay Cmax/D
Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days.</description>
        <time_frame>Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days</time_frame>
        <population>12 subjects from both Stratum 1 and 2 were analyzed together as one group as per statistical analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Subjects Consented to PK Collection</title>
            <description>Includes study subjects from either stratum that signed an optional consent to have PK's collected</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax)</title>
          <description>Pharmacokinetic assay Cmax/D
Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days.</description>
          <population>12 subjects from both Stratum 1 and 2 were analyzed together as one group as per statistical analysis plan.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11958" lower_limit="5123" upper_limit="18793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC)</title>
        <description>Pharmacokinetic assay AUC(0-6 hr)/D
Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days</description>
        <time_frame>0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose on two different days</time_frame>
        <population>12 subjects from both Stratum 1 and 2 were analyzed together as one group as per statistical analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Subjects Consented to PK Collection</title>
            <description>Includes study subjects from either stratum that signed an optional consent to have PK's collected</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC)</title>
          <description>Pharmacokinetic assay AUC(0-6 hr)/D
Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days</description>
          <population>12 subjects from both Stratum 1 and 2 were analyzed together as one group as per statistical analysis plan.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47024" lower_limit="23868" upper_limit="70180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Peak Plasma Concentration (Tmax)</title>
        <description>Pharmacokinetic assay- tmax, hr
Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days</description>
        <time_frame>0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose on two different days</time_frame>
        <population>12 subjects from both Stratum 1 and 2 were analyzed together as one group as per statistical analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Subjects Consented to PK Collection</title>
            <description>Includes study subjects from either stratum that signed an optional consent to have PK's collected</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Peak Plasma Concentration (Tmax)</title>
          <description>Pharmacokinetic assay- tmax, hr
Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days</description>
          <population>12 subjects from both Stratum 1 and 2 were analyzed together as one group as per statistical analysis plan.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="1.9" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion plus 30 days, an average of 2 years.</time_frame>
      <desc>All subjects that received at least one dose of DFMO. Since both arms received the same exact treatment, they were combined into one reporting group.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Study Subjects</title>
          <description>All subjects that received at least one dose of DFMO. Since both arms received the same exact treatment, they were combined into one reporting group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>hearing loss</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling of Eye</sub_title>
                <description>Eye swelling result of brain mass that has been confirmed as metastatic recurrent neuroblastoma.
Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>All Unrelated</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>All Unrelated</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Obstruction</sub_title>
                <description>gastric obstruction secondary to adhesions from previous surgery. Resolved after surgical correction.
Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>All Unrelated</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Femur Fracture- Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Disorder</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Benign vascular lesion</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decrease</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing Loss</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT elevation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>AST elevation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Giselle Sholler</name_or_title>
      <organization>Beat Childhood Cancer</organization>
      <phone>6162670334</phone>
      <email>giselle.sholler@helendevoschildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

